Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA

Investegate announcements from Junshi Biosciences, Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA

Related Keywords

Guangzhou ,Guangdong ,China ,Shanghai ,United States ,Suzhou ,Jiangsu ,Beijing ,Maryland ,Canada ,San Francisco ,California ,Chinese ,Denny Lanfear ,Mcdavid Stilwell ,Coherus Biosciences ,Junshi Biosciences ,Zhi Li ,Brian Grancagnolo ,Exchange Commission On ,Ir Team ,Coherus Biosciences Inc ,Drug Administration ,Shanghai Junshi Biosciences Co Ltd ,Exchange Commission ,National Reimbursement Drug List ,National Medical Products Administration ,Pr Team ,Coherus Receive Complete Response Letter ,Biologics License Application ,Nasopharyngeal Carcinoma ,Southeast Asia ,New Drug Applications ,Breakthrough Therapy ,Fast Track ,Orphan Drug Designation ,Chinese Academy ,Emergency Use Authorizations ,Private Securities Litigation Reform Act ,Coheru Annual Report ,Contact Information ,Investegate Announcements ,Investegate Company Announcements ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,